Development and scale‐up of a commercial fed batch refolding process for an anti‐ CD 22 two chain immunotoxin-Reference-Cited by-同舟云学术

Development and scale‐up of a commercial fed batch refolding process for an anti‐ CD 22 two chain immunotoxin

Published:2014-09-02 Issue:6 Volume:30 Page:1380-1389
ISSN:8756-7938
Container-title:Biotechnology Progress
language:en
Short-container-title:Biotechnol Progress

Author:

Linke Thomas¹,Aspelund Matthew T.¹,Thompson Christopher¹,Xi Guoling¹,Fulton Andrew¹,Wendeler Michaela¹,Pabst Timothy M.¹,Wang Xiangyang¹,Wang William K.¹,Ram Kripa¹,Hunter Alan K.¹

Affiliation:

1. Dept. of Purification Process SciencesMedImmune, One MedImmune WayGaithersburg MD20878

Publisher

Wiley

Subject

Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/btpr.1983

Reference33 articles.

1. Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies

2. Immunotoxins containing Pseudomonas exotoxin A: a short history;Pastan I;Cancer Immunol Immunother,2003

3. Immunotoxin therapy of cancer

4. Immunotoxin Treatment of Cancer

5. CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response;Vaccines;2024-06-14

2. Mechanistic Modeling of Size Exclusion Chromatography-Assisted In Vitro Refolding of the Recombinant Biosimilar Teriparatide (PTH-34);ACS Omega;2024-01-05

3. Chromatography assisted in-vitro refolding and purification of recombinant peptibody: Recombinant Romiplostim a case study;International Journal of Biological Macromolecules;2023-09

4. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma;International Immunopharmacology;2022-12

5. Refolding in the modern biopharmaceutical industry;Biotechnology Advances;2022-12